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Abstract
The strategy used to treat HCV infection depends on the genotype involved. An accurate and reliable genotyping method is
therefore of paramount importance. We describe here, for the first time, the use of a liquid microarray for HCV genotyping.
This liquid microarray is based on the 59UTR — the most highly conserved region of HCV — and the variable region NS5B
sequence. The simultaneous genotyping of two regions can be used to confirm findings and should detect inter-genotypic
recombination. Plasma samples from 78 patients infected with viruses with genotypes and subtypes determined in the
Versant
TM HCV Genotype Assay LiPA (version I; Siemens Medical Solutions, Diagnostics Division, Fernwald, Germany) were
tested with our new liquid microarray method. This method successfully determined the genotypes of 74 of the 78 samples
previously genotyped in the Versant
TM HCV Genotype Assay LiPA (74/78, 95%). The concordance between the two methods
was 100% for genotype determination (74/74). At the subtype level, all 3a and 2b samples gave identical results with both
methods (17/17 and 7/7, respectively). Two 2c samples were correctly identified by microarray, but could only be
determined to the genotype level with the Versant
TM HCV assay. Genotype ‘‘1’’ subtypes (1a and 1b) were correctly
identified by the Versant
TM HCV assay and the microarray in 68% and 40% of cases, respectively. No genotype discordance
was found for any sample. HCV was successfully genotyped with both methods, and this is of prime importance for
treatment planning. Liquid microarray assays may therefore be added to the list of methods suitable for HCV genotyping. It
provides comparable results and may readily be adapted for the detection of other viruses frequently co-infecting HCV
patients. Liquid array technology is thus a reliable and promising platform for HCV genotyping.
Citation: Duarte CAB, Foti L, Nakatani SM, Riediger IN, Poersch CO, et al. (2010) A Novel Hepatitis C Virus Genotyping Method Based on Liquid Microarray. PLoS
ONE 5(9): e12822. doi:10.1371/journal.pone.0012822
Editor: Linqi Zhang, Tsinghua University, China
Received May 13, 2010; Accepted August 26, 2010; Published September 20, 2010
Copyright:  2010 Duarte et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This investigation received financial support from Conselho Nacional de Desenvolvimento Cientı ´fico e Tecnolo ´gico (CNPq), Instituto Nacional de
Cie ˆncia e Tecnologia em Diagno ´sticos para a Sau ´de Pu ´blica, FIOCRUZ. MAK holds CNPq research fellowships. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mkrieger@fiocruz.br
Introduction
Hepatitis C virus (HCV) infection occurs worldwide and it has
been estimated that 180 million people are infected globally [1].
This infection is a common cause of chronic liver disease and the
most common indication for liver transplantation [2,3]. Treatment
should be tailored according to the genotype of the virus. Patients
with genotype 1 viruses should be treated for 48 weeks with
peginterferon alfa-2a plus standard weight-based ribavirin,
whereas patients with viruses of genotypes 2 and 3 should be
treated with peginterferon alfa-2a plus low-dose ribavirin for 24
weeks [4]. The most strongly conserved regions of the HCV
genome are the 59 untranslated region (59UTR), and the terminal
99 bases of the 39 untranslated region [5]. The diagnostic assays
based on the 59UTR currently used have an acceptable accuracy,
displaying more than 95% concordance with the results of
genotyping based on sequencing of the NS5B polymerase gene
in the variable region. The results of the sequencing of this region
are consistent with those of whole-genome sequencing for
genotype/subtype determination [6]. Two commercial assays are
frequently used to determine HCV genotypes: the TruGene 59NC
HCV Genotyping kit (Siemens Healthcare Diagnostics Division,
Tarrytown, NY), based on direct sequence analysis of the 59UTR
(untranslated region), and the Versant
TM HCV Genotype Assay
LiPA (version I; Siemens Medical Solutions, Diagnostics Division,
Fernwald, Germany), based on reverse hybridization analysis with
genotype-specific oligonucleotide probes binding to the 59UTR
[7]. Given the importance of HCV genotyping, an accurate,
sensitive, cost-effective and reproducible assay is much needed.
Ideally, any diagnostic method for HCV genotyping should be
able to distinguish between all the relevant variants simultaneous-
ly. We describe here, for the first time, an HCV genotyping
method based on liquid microarray technology (xMAP Technol-
ogy, Luminex Corp, Austin, Texas).
Liquid microarray technology has been used for the detection of
many different pathogens [8,9,10]. One of its key properties is an
extensive multiplexing capacity, making it possible to detect
different nucleic acid targets simultaneously. This is particularly
important for HCV genotyping, as there are many different HCV
genotypes and subtypes [11]. HCV genotyping on the basis of two
different viral genome regions has the advantage that the results
for one region confirm those for the other, and should also make it
possible to detect rare cases of inter-genotypic recombination
[12,13].
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genotyping based on the simultaneous analysis of two genomic
regions, the 59UTR and NS5B regions, (nonstructural region 5B),
for all samples tested. The analysis of two regions provides a means
of confirming the results obtained and could potentially detect
inter-genotypic recombination. The liquid microarray HCV
genotyping test performed as well as the test currently used
(Versant
TM HCV genotype Assay LiPA). It also has the advantage
of being less subjective as it does not rely on visual reading as
LiPA, but Luminex software generated numerical value (MFI)
[6,14]. Visual reading interpretation may be subjected to inter-
operators’ variation and possible misinterpretation [15].
Results
All 78 samples were tested in duplicate, from RNA extraction and
RT-PCR to hybridization and Luminex reading. According to the
criteria outlined in the materials and methods, 74 samples generated
a specific signal for at least one microsphere/probe set. All probes
binding to region 59UTR and six of the 10 probes binding to NS5B
generated hybridization signals with various samples (figure 1). The
netMFI values obtained for all samples are shown in the supporting
information (table S1). The hybridization of PCR products to specific
59UTR and NS5B probes attached to microspheres resulted in
different netMFI profiles. Genotype 1 samples invariably gave a
hybridization signal for probe U11 (59UTR region). However, for
genotype 1strainsalsogiving hybridizationsignalswithNS5Bprobes,
subtypes were identified as 1a (signal for probe NS1a) or 1b (signal for
probe NS1bx). Samples identified as subtype 2b displayed one of the
following three combinations: signal for the U2bx probe only, signals
forU2bx+NS2b or signals for U2By +NS2b.Samplesidentified was
subtype 2c hybridized with the U2a/cx + U2a/cy + NS2c probes or
the U2a/cx + NS2c probes. One sample giving a signal only with the
U2a/cxprobewasclassifiedassubtype2aor2c.Samplesidentifiedas
subtype 3a displayed one of the following four combinations: signal
for U3a1 only, signals for U3a1 + NS3ax, signals for U3a1 + NS3ay
or signals for U3a1 + NS3ax + NS3ay (table 1).
Microarray genotype determination was not possible for four
samples subtyped by the Versant
TM HCV assay as 1a, 1b, 2 and
3a. A comparison of the genotype/subtype results obtained with
the two methods is shown in the table 2.
Clinical sensitivity
Seventy-four of the 78 samples previously tested by Versant
TM,
were successfully genotyped by the liquid microarray method (74/
78, 95%). The concordance between the two methods for these 74
samples was 100% for genotype. The following genotypes were
identified: genotype 1 (47 samples), genotype 2 (10 samples) and
genotype 3 (17 samples). At subtype level, the concordance
between the two methods was 100% for subtypes 3a (17/17) and
2b (7/7). One samples was identified as 2a or 2c (2a by
sequencing) and two samples were identified as 2c by liquid
microarray analysis, confirmed by sequencing, whereas they were
identified only to genotype level by Versant
TM. Nine of the 12
subtype 1a identifications and one of the seven subtype 1b
identifications were consistent with the results of Versant
TM
analysis. The remaining samples were identified only to the
genotype level, as genotype ‘‘1’’, by Versant
TM. No PCR products
for the NS5B region were obtained for 28 genotype 1 samples for
which subtype was not determined.
Specificity
We evaluated the rate of false positive detection with the
genotype-specific primer-probe sets, by testing thirty-eight of the
positive specimens for the following viruses: hepatitis B virus
(n=12) and hepatitis A virus (n=7), for which tests are often
carried out in suspected cases of HCV infection; HIV (n=12),
which was selected for study due to the high incidence of HIV-
HCV co-infection in the population studied and dengue virus
(n=7), which belongs to the same family (Flaviviridae) as HCV.
The genotype primer-probe sets were found to be specific for the
various genotypes. They gave no false positive results with other
common hepatitis viruses (HAV and HBV), dengue virus or
HIV. Furthermore, two negative control samples testing negative
with the Versant
TM HCV assay, also tested negative with the
microarray test.
Discussion
We describe here an HCV genotyping assay based on liquid
microarray technology and including 16 hybridization probes
specific for different HCV genotypes and subtypes and one set of
Figure 1. Mean netMFI and standard deviation (SD). MFI: Median fluorescence intensity; netMFI: MFI - mean background (blank) MFI.*Bkg=
background. Hybridization signals above background were not detected for probes NS1by, NS1c, NS2ax and NS2ay.
doi:10.1371/journal.pone.0012822.g001
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detection and genotyping (59UTR and NS5B).
The liquid microarray assay described here had excellent
clinical sensitivity (95%) for genotype determination. RNA
instability and secondary structures have made it difficult to
develop molecular tests for HCV. The viruses circulating in Brazil
are almost exclusively of genotypes 1, 2 and 3 [16] and the
microarray test would fulfill the needs of this large country for
HCV genotyping. The clinical sensitivity obtained for this test is
similar with published findings for other tests [17]. Only samples
previously tested with the Versant
TM HCV assay were available
for microarray testing. No samples for which Versant
TM HCV had
failed to assign a genotype were tested with the microarray. A
study including parallel sample testing would provide unbiased
conclusions regarding clinical sensitivity.
Versant
TM HCV Genotype Assay LiPA is by far the most used
test in Brazil for HCV genotyping; its high sensitivity and
specificity (close to 99%) has made it a reference standard in
previous studies [6,18]. Sample selection was based on HCV
genotype as had been previously assigned using the LiPA.
Performance was evaluated by comparing the genotyping results
obtained from microarray with those generated by LiPA.
No PCR product for the targeted regions was obtained for four
samples. This failure to generate a PCR product made genotyping
impossible for these samples. Possible reasons for this lack of a
PCR product include low viral titers for these samples and the
inefficiency of PCR due to the presence of an inhibitor with no
apparent effect on the LiPA assay.
As shown in table 3, some genotypes/subtypes were detected
with more than one probe, due to the level of nucleotide variability
even within subtypes. For instance, samples identified as subtype
3a, were correctly classified as such based on four different possible
hybridization signal outcomes, as described in the results. In the
particular case of subtype 3a, 59UTR information alone is
sufficient to assign a subtype. We were therefore able to classify
samples with a hybridization signal only for the 59UTR probe U3a
in addition to those that also gave signals with probes designed to
bind to the NS5B region (NS3ax, NS3ay or both).
By contrast, hybridization patterns with the 59UTR probe are
not sufficiently informative for the subtyping of genotype 1 and 2
viruses. For these genotypes, information concerning the NS5B
region is required for the accurate determination of subtype. No 1c
subtype virus was identified with the Versant
TM HCV assay and,
consistent with this finding, no signal was obtained with the NS1c
probe.
Information about the 59UTR was sufficient to assign samples
to subtype 2b, but not to differentiate between subtypes 2a and 2c.
Differentiation between these two subtypes required hybridization
signals for probes binding to the NS5B region. Two samples were
classified as subtype 2c because they gave a hybridization signal
with the NS2c probe, and one sample was identified as subtype
Table 1. Hybridization signal profiles.
Samples Genotype
1 U11 U2a/cx U2a/cy U2bx U2by U3a NS1a NS1bx NS1by NS1c NS2ax NS2ay NS2b NS2c NS3ax NS3ay
28 1 + - - --- -- - -- - --- -
12 1a + --- - - + --- --- - - -
71 b + --- - - - + -- --- - - -
12 a o r 2 c - ++--- -- - -- - --- -
12 b - - - + -- -- - -- - + -- -
32 b - - - + -- -- - -- - + -- -
32 b - - - + -- -- - -- - --- -
12 c - ++--- -- - -- - -+ --
12 c - + - --- -- - -- - -+ --
23 a - - - - - + - --- --- - ++
43 a - - - - - + - --- --- - + -
33 a - - - - - + - --- --- - - +
83 a - - - - - + - --- --- - - -
1Genotype/subtype obtained by microarray analysis.
1, 1a, 1b, 2a, 2b, 2c and 3a: HCV genotypes/subtypes.
59UTR and NS5B probes specificity - U11: Genotype 1; U2a/cx and U2a/cy: Subtypes 2a and 2c;
U2bx and U2by: Subtype 2b; U3a: Subtype 3a; NS1a: Subtype 1a; NS1bx and NS1by: Subtype 1b; NS1c: Subtype 1c;
NS2ax and NS2ay: Subtype 2a; NS2b: Subtype 2b; NS2c: Subtype 2c; NS3ax and NS3ay: Subtype 3a.
(+): Specific hybridization signal.
(-): No specific hybridization signal.
doi:10.1371/journal.pone.0012822.t001
Table 2. Comparison of the results obtained with the
microarray and Versant
TM HCV.
Samples Microarray Versant
TM HCV
23 1 1b
51 1
31 a 1
91 a 1 a
71 b 1
12 a o r 2 c 2
72 b 2 b
22 c 2
17 3a 3a
Samples: number of genotype and/or subtype agreement between tests.
doi:10.1371/journal.pone.0012822.t002
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probe, which hybridizes to both subtypes, and the absence of a
signal for probes binding to the NS5B region.
Some cross-hybridization was observed between three of the 10
genotype 2 samples, with 59UTR probes only. The gen997, gen1859
and genat samples were identified as belonging to subtypes ‘‘2a or
2c’’, 2b and 2c, respectively. For gen997 and genat the netMFI
obtained with the U2a/cx probe was more than twice that
obtained with the U2by probe (supporting information, table S1).
The opposite pattern was observed with gen1859, the netMFI for
the U2by probe being more than four times that for the 2a/cx
probe. This cross-hybridization was attributed to the high
similarity between the probes (table 3). Nonetheless, probes were
designed to bind at the same positions, and any mismatch
decreases binding to the corresponding probe, thereby reducing
the resulting netMFI to levels lower than those for perfect
hybridization in a situation of competitive dynamics. This is why it
was possible to determine genotype/subtype in these samples, even
in the presence of some cross-hybridization.
The lower efficiency of determination for subtypes 1a/1b was
due to the failure of multiplex PCR to amplify the NS5B region in
a significant number of the samples tested. This failure of
multiplex PCR may result from the high nucleotide sequence
diversity of the NS5B region, impairing primer annealing. Subtype
determination based on the 59UTR region was possible in all
samples for subtypes 2b, and 3a, but it has been demonstrated that
the 59UTR region alone is not sufficiently accurate to distinguish
between genotypes 1a and 1b in many cases [19,20]. Further
improvements in PCR amplification of the NS5B region are
required, to increase the efficiency of subtype discrimination. This
could be accomplished by decreasing the degeneracy of the primer
set for the amplification of the NS5B region. Two separate PCRs
for the NS5B region, for genotype 1 and genotype 2, could be
carried out in parallel.
Even though 1a/1b subtype determination in this assay was
below of expected, it is worth considering that subtyping is
irrelevant as a consideration for therapeutic strategy, being of only
epidemiological importance [4]. The microarray assay was able of
consistently determining genotype which matters on treatment
planning and was the main goal of this study.
Furthermore, the microarray format potentially can be adapted
to cover other genotypes prevailing in other geographic areas as it
has been conceived to permit inclusion of probes up to the
theoretical number of one hundred [14].
This is facilitated by the presence of TMAC in the buffer, which
homogenizes the hybridization temperatures of different probes by
stabilizing A/T pairing. The hybridization temperature used is
therefore much more dependent on the extension function of the
probe than on its nucleotide composition [21].
Inter-genotypic recombination detection is rare, but an assay
with the capacity to detect it could prevent inappropriate
treatment. This is particularly important for tests based on the
59UTR region. For example, genotyping based on the 59UTR
region of a recombinant strain would lead to treatment for the
genotype detected at that site, but the virus might have the NS5
region of another genotype, and this second region is known to be
associated with IFN susceptibility [22]. All of this is hypothetical,
and further, well designed studies would be required for
Table 3. Primers and probes for the 59UTR and NS5B regions.
Oligonucleotide Genomic region Genotype/subtype Modification Sequence 59R39 Positioning*
HCV1F 59UTR biotin CGGGAGAGCCATAGTGGT 130–147
NSNOF NS5B biotin ACMAAGCYCAAACTCACTCCAWT 1597–1621
HCVRX 59UTR CGCRACCCAACRCTACT 256–273
NSNOR NS5B CAYGMGACACGCTGTGA 1685–1702
U11 59UTR amino-12C ACCCGGTCGTCCTGGCAATT 179–198
U3a 59UTR 3a amino-12C ACCCGGTCACCCCAGCGATT 179–198
U2a/cx 59UTR 2a & 2c amino-12C ACCCAGTCTTCCCGGCAATT 179–198
U2a/cy 59UTR 2a & 2c amino-12C ACCCGGTCTTCCCGGCAATT 179–198
U2bx 59UTR 2b amino-12C ACCCAGTCTTTCCGGTAATT 179–198
U2by 59UTR 2b amino-12C ACCCAGTCTTTCCGGCAATT 179–198
NS1a NS5B 1a amino-12C GTAGCCAGCCGTGAACCA 1652–1668
NS1bx NS5B 1b amino-12C GTAACCAGCAACGAACCA 1652–1668
NS1by NS5B 1b amino-12C GTAGCCAGCAATGAACCA 1652–1668
NS1c NS5B 1c amino-12C GTAACCGCCCGTGAACCA 1652–1668
NS2ax NS5B 2a amino-12C GGCGCCGACAGTGAACCA 1652–1668
NS2ay NS5B 2a amino-12C GGCGCCGACGGTAAACCA 1652–1668
NS2b NS5B 2b amino-12C GGCGCCCACGGTGAACCA 1652–1668
NS2c NS5B 2c amino-12C AGCGCTGACGGTGAACCA 1652–1668
NS3ax NS5B 3a amino-12C GACACCAACCGTAAACCA 1652–1668
NS3ay NS5B 3a amino-12C GACGCCAACCGTAAACCA 1652–1668
*Reference sequence (GenBank, AF009606). M: A or C; Y: C or T; W: A or T; R: A or G.
59UTR (untranslated region) specific primers: HCV1F (forward), HCVRX (reverse).
NS5B (nonstructural 5B region) specific primers: NSNOF (forward), NSNOR (reverse).
Modification: Forward primer had 59 biotin added for streptavidin-R-phycoerythrin (SA-PE) ligation.
Probes had 59 amino-12C (carbon linker) added for ligation to the microspheres.
doi:10.1371/journal.pone.0012822.t003
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found among the 74 samples tested, despite the assay having been
designed to detect such recombination. However, this lack of
detection may be due to the small number of samples, as inter-
genotypic recombination is a rare event.
Despite the small number of samples evaluated for specificity,
we detected no non-specific hybridization of the probes used to
non-HCV targets. This aspect is particularly important, given the
high prevalence of HIV co-infection in HCV patients and the risk
factors common to these two types of infection.
The total time required for performing this assay was three and
a half hours, virtually the same as required for LiPA v. 1. The
estimated reaction cost of microarray assay was eight times lower
than that of available commercial methods in Brazil. In order to
estimate the cost of the microarray assay, costs of NucliSens
EasyMAG extraction kit (bioMerieux), Omniscript Reverse
Transcriptase (QiagenH), Taq polymeraseH, primers and probe
sets (synthesized by Invitrogen), RNase inhibitor (Invitrogen), and
Luminex beads and reagents were taken for comparison.
Assessment of the final costs related to LiPA v.1 included the
AmplicorH Hepatitis C Virus-HCV-Test, version 2.0 Roche (for
PCR product generation) and the VERSANT
TM HCV Genotype
Assay-LiPA v.1 (Siemens). Tests costs estimation was based on the
currently available commercial reagent prices in Brazil at the time
the study was conducted. Equipment maintenance, human
resources and other indirect costs were not taken into account
for comparison and calculation. The reduction costs associated
with this new assay would make possible to use it in all Brazil
regions, many of which still does not have HCV genotyping
capacity, considerably impairing treatment strategy.
When choosing a molecular diagnostic method, it is also
important to take into account the hands-on time and throughput
potential. All the steps of microarray assays can be automated,
overcoming the need for interpretation by highly skilled staff and
the possible errors associated with handling [23,24,25].
In conclusion, this new xMAP Luminex assay system is rapid,
sensitive, and specific for the purposes of HCV genotyping. It can
be used for the simultaneous detection of different HCV genotypes
and subtypes. This system is highly flexible, allowing the inclusion
of new sequences, such as genetic variants, or additional viruses,
by the simple addition of appropriate microsphere sets to the
multiplexed mixture. Liquid microarray technology should, in the
near future, become widely used in nucleic acid detection.
Materials and Methods
Samples
Plasma was obtained from blood samples collected into
ethylenediaminetetraacetic acid (EDTA) between January 2007
and February 2008. These samples were obtained from 78 patients
with chronic HCV infection at the Parana ´ State Reference
Laboratory of Health (LACEN-PR). Plasma was stored at -70 uC
until use. The HCV genotypes for these samples had previously
been determined with the Versant
TM HCV genotype Assay LiPA
(version I; Siemens Medical Solutions, Diagnostics Division,
Fernwald, Germany). The sequences obtained have been
submitted to GenBank and can be retrieved under accession
numbers FJ159697 to FJ159843.
The study protocol was approved by the Ethics Committee
of University of Sa ˜o Paulo (CAAE -2546.0.015.000-05). The
requirement for written informed consent was waived by the IRB
because the samples used were coded upon collection and storage.
Personal identifiers have been removed, avoiding patient identi-
fication completely. The samples cannot be traced to individual
patients. Besides, the study did not present any risks for the
patients and involved no procedures for which written consent is
normally required outside of the research context.
RNA extraction
RNA was extracted from 200 ml of EDTA-treated plasma from
each patient sample, with the Nuclisens easyMAG automated
platform (bioMerieux, Inc., Boxtel, Netherlands), used according
to the manufacturer’s instructions. Briefly, 200 ml of an EDTA-
treated plasma sample was added to 2 ml of lysis buffer and the
mixture was incubated for 10 min at room temperature. The lysed
sample was then transferred to the well of a plastic vessel con-
taining 100 ml of magnetic silica. Automatic magnetic separation
was then carried out and nucleic acid was recovered in 20 ml
elution buffer.
Primers and probe design
All the probes and primers used in this assay were designed on
the basis of consensus sequences deposited at Los Alamos National
Laboratory (Hepatitis C Virus Database Project) http://hcv.lanl.
gov/components/hcv-b/GET_ALIGNMENTS/get_alignment.
comp. Two sets of primers were designed: one set for the 59UTR
region and the other for the NS5B region. The forward primers
were59 biotinylated. The oligonucleotides (probes) to be attached to
the microspheres were designed so as to contain a 59 amino 12-
carbon linker. These probes were designed to be complementary to
the internal portion of the biotinylated strand from PCR products:
six probes for the 59UTR region and 10 for the NS5B region
(table 3).
Reverse transcription and PCR
We carried out 88 reverse transcription reactions (78 HCV
samples and 10 negative controls) with the OmniscriptH Reverse
Transcription Kit (Qiagen). Targets were reverse transcribed in
20 ml reaction mixtures containing 106RT buffer, 10 units RNase
inhibitor, 4 units Omniscript Reverse Transcriptase, 4 mg random
primers, 0.5 mM of each dNTP and 12.5 ml RNA, for one hour at
37uC. A multiplex PCR was then carried out in 106PCR buffer,
0.3 units Taq polymerase, 1.5 mM MgCl2, 200 mM of each dNTP,
0.2 mM each of the HCVF/HCVRX primers and 0.5 mM each of
the NSNOF/NSNOR primers. PCR was conducted in a Peltier
Thermal Cycler (MJ96+/MJ966), by incubation at 94uC for
5 min, followed by 35 cycles of denaturation at 94uC for 30 s,
annealing at 56.8uC for 30 s, and extension at 72uC for 60 s.
There was then a final extension phase at 72uC for 3 min, and
reactions were held at 4uC thereafter.
Attachment of probes to microspheres
Probes, purchased with a 59 amino 12-carbon linker (The
Midland Certified Reagent Company, Midland, TX), were
covalently coupled to carboxylated microspheres (Luminex Corp.,
Austin, TX), using a carbodiimide coupling procedure. Carbox-
ylated microspheres were prepared by placing 200 ml of stock
suspension in a 1.5 ml microcentrifuge tube and centrifuging at
8,000 g for 2 min. The supernatant (storage buffer) was decanted,
and the microspheres were resuspended in 50 ml of 0.1 M MES
[2-(N-morpholino) ethanesulfonic acid], pH 4.5. Microspheres
were exposed to light as little as possible to prevent photobleach-
ing, which prevents the Luminex detection system from registering
the individual microsphere codes. Once suspended, the micro-
spheres were vortexed and 2 ml of 100 mM amino-modified probe
suspension was added. Aliquots of desiccated 1-ethyl-3-(dimethy-
laminopropyl) carbodiimide HCl (EDC) powder (Pierce Biotech-
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We added 2.5 ml of 10 mg/ml EDC to each mixture, for the
attachment of the amine-modified probes to the carboxylated
microspheres. The microsphere mixture was incubated in the dark
at room temperature for 30 min. A second aliquot of 10 mg/ml
EDC was then added and the suspension incubated for another
30 min. After incubation with EDC, 1 ml of 0.02% polyoxyethy-
lenesorbitan monolaurate (Tween 20) was added and the micro-
spheres were vortexed and then centrifuged at 8,000 g for 2 min.
The supernatant was removed by aspiration. We then added 1 ml
of 0.1% sodium dodecyl sulfate. The microspheres were vortexed
and then centrifuged again at 8,000 g for 2 min. The supernatant
was once again removed by aspiration. The microspheres were
then resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA,
pH 8.0) and the number of microspheres per microliter was
determined with a hemacytometer. Sets of microspheres with the
newly attached probes were then stored at 4uC for future use.
Hybridization with PCR products
The hybridization assay was based on the binding of
complementary biotinylated PCR products to the probes attached
to the microspheres. The assay was performed in a 96-well, clear,
low-profile, flat-top PCR microplate (Axygen Inc). The final
reaction volume was 50 ml, including 33 ml of microsphere mixture
and 17 ml of the amplified product or TE buffer (blank). The
microsphere mixture was prepared by adding a calculated volume
of each microsphere set to 1.56 TMAC buffer (1.56 TMAC
buffer is 4.5 M tetramethylammonium chloride, 75 mM Tris-HCl
pH 8.0, 6 mM EDTA and 0.15% Sarkosyl), to achieve a
concentration of 2,500 microspheres per set in 33 ml. We added
5 ml of PCR product; the titer plate was sealed and the amplified
DNA was denatured at 95uC for 5 min and then incubated for
30 min at 55uC in a thermocycler (Peltier Thermal Cycler,
MJ96+/MJ966). We then added 25 mlo fa1 5mg/ml dilution of
streptavidin-R-phycoerythrin (SA-PE) (Molecular Probes, Eugene,
OR). The plate was incubated for 15 min at 55uC and read on a
heated stage at the same temperature as the Luminex 100
platform. This platform analyzes polystyrene microspheres of
5.6 mm that are internally dyed with two different fluorochromes
mixed in different ratios to generate microsphere populations with
specific spectral addresses. These microspheres are classified by
two lasers, a 635-nm red diode laser to detect the internal dyes of
the microspheres and a 532-nm laser that excites the reporter
molecule, R-phycoerythrin (PE). Each sample was run in duplicate
with ten blanks per plate. The median fluorescence intensity (MFI)
of the SA-PE conjugate bound to 100 microspheres of each
population was reported.
Reading the MFI signal
Median fluorescence intensity (MFI) was determined for each
reaction individually. The mean background (blank) MFI was then
subtracted, generating netMFI. A netMFI greater than the mean
background MFI plus 10 times the standard deviation (SD) was
considered to indicate specific hybridization.
Supporting Information
Table S1 NetMFI from all samples. * Samples previously
genotyped by VersantTM HCV. ¤ Samples with positive net
MFI signal. ¥ Samples failured to amplify NS5b region.
Found at: doi:10.1371/journal.pone.0012822.s001 (0.08 MB
XLS)
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